Douglas Emmett, Inc.'s stock price has experienced a significant decline over the past six months, dropping 37.08% to $10.25 as of September 18, 2026, from $16.29 on September 22, 2025. Over the last 12 months, the stock's price decreased by 34.74%, and in the past month, it saw a 14.24% decrease. Key events impacting the stock include a surprise Q2 2026 quarterly loss of $0.02 per share, missing consensus estimates despite a 2% year-over-year revenue increase. In Q2 2026, the company achieved strong leasing momentum, signing 960,000 square feet of leases, and management paused a residential conversion project due to renewed interest from large office tenants. However, office same-property cash Net Operating Income decreased by 1.2% in the second quarter, and management lowered office occupancy guidance to between 75% and 77%. Douglas Emmett acquired the Bedford Collection medical office properties through a joint venture for $260 million. The company declared quarterly cash dividends of $0.19 per share on September 3, 2026, and May 28, 2026. Q1 2026 earnings results were released, and Andy Cohen was elected to the Board of Directors. Analyst coverage has been largely neutral, with some firms trimming price targets, indicating a more cautious outlook. Despite the stock's performance, institutional investors, including BlackRock, Bank of America, HSBC, Deutsche Bank, Palisade Capital, and Bamco, have disclosed new or increased stakes, indicating they remain net buyers.
